Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

Despite the significant advances in the treatment of multiple myeloma (MM), this disease is still considered incurable because of relapse and chemotherapy resistance, underscoring the need to seek novel therapies with different mechanisms. Anlotinib, a novel multi-targeted tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yang, Shan, Huizhuang, Liu, Meng, Liu, Jia, Zhang, Zilu, Xu, Xiaoguang, Liu, Yue, Xu, Hanzhang, Lei, Hu, Yu, Miao, Zhang, Xingming, Liu, Wanting, Bu, Zhilei, Fang, Zhixiao, Ji, Yanjie, Yan, Hua, Gu, Weiying, Wu, Yingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046985/
https://www.ncbi.nlm.nih.gov/pubmed/33854043
http://dx.doi.org/10.1038/s41419-021-03685-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046985/
https://www.ncbi.nlm.nih.gov/pubmed/33854043
http://dx.doi.org/10.1038/s41419-021-03685-w

Ejemplares similares